Lactobacillus rhamnosus B16 regulates lipid metabolism homeostasis by producing acetic acid

作者：Zhengping Che, Juan Huang, Shiyi Wen, Xingxing Chai, Shaobing Zhang, Haibo Yu, Bihua Lin, Yanfang Liang, Ziyu Ye, Jincheng Zeng · 发表于：Journal of Translational Medicine · 年份：2025 · DOI：10.1186/s12967-025-07228-1 · 被引用次数：7 · 研究领域：Probiotics and Fermented Foods、Cholesterol and Lipid Metabolism、Biochemical Analysis and Sensing Techniques

BACKGROUND: Hyperlipidemia, a chronic disorder caused by abnormal lipid metabolism, increases risks of atherosclerosis and cardiovascular diseases. Current single-target drugs have limited efficacy and side effects, prompting interest in probiotics such as Lactobacillus rhamnosus, though their mechanisms remain unclear. METHODS: A novel Lactobacillus rhamnosus strain from healthy human feces was identified via API 50CH and ANI analysis. Integrated genomic and proteomic analyses were performed on the novel Lactobacillus rhamnosus B16 (L. rB16) strain to characterize its lipid metabolism-related traits. A cholesterol degradation assay, gastrointestinal fluid tolerance test, and biofilm formation assay were used to evaluate the functional properties of L. rB16, while foam cell models were employed to assess its cholesterol-lowering effects. Western blotting was used to determine the expression levels of key lipid metabolism-associated proteins (LXRα, ABCA1, ABCG1, HMGCR, and SREBP1) in foam cells treated with heat-inactivated L. rB16 (HI-L. rB16). For in vivo validation, a high-fat diet (HFD)-induced hyperlipidemic mouse model was established, and analyses including serum lipid profiling, histological examination, and immunohistochemical staining were conducted. Metabolomic and short-chain fatty acids (SCFAs) analyses identified key metabolites, validated by sodium acetate treatment. RESULTS: We identified a novel strain of L. rB16 from healthy human feces, which had cholesterol...